With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.
The resulting compound (124 mg, 0.350 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (68.6 mg, 0.350 mmol) to afford the desired title compound (74.2 mg, yield 47%) as a yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.85 (1H, brs), 9.58 (1H, d, J=7.0 Hz), 8.16 (1H, d, J=2.6 Hz), 7.88 (1H, dd, J=7.4 Hz, 5.4 Hz), 7.74-7.62 (2H, m), 7.40 (1H, d, J=7.4 Hz), 7.38 (1H, d, J=8.2 Hz), 6.93-6.84 (1H, m), 5.19 (1H, m), 5.00 (1H, m), 4.08-3.81 (2H, m), 3.58-3.16 (2H, m), 2.15-1.92 (2H, m), 1.88-1.48 (4H, m), 0.92 (3H, t, J=7.4 Hz). IR (KBr) cm-1: 2950, 1690, 1630, 1480, 1215. MS (ESI, m/z): 454 (M+H)+. HRMS (ESI, m/z): 454.1890 (Calcd for C23H25FN5O4: 454.1891).
The synthetic route of 1204-75-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider